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 24 
Abstract 25 
Objectives: To evaluate the analgesic effect and the absorption of buprenorphine after buccal 26 
administration in cats with oral disease. 27 
Methods: Six adult client-owned cats with chronic gingivostomatitis (weighing 5.1kg +/- 1.1kg) were 28 
recruited for a randomised, prospective, blinded, saline controlled crossover study. Pain scores, dental 29 
examination, stomatitis score and buccal pH measurement were conducted on day 1 under sedation in 30 
all cats. On day 2, animals were randomized in two groups and administered one of the two treatments 31 
buccally (group A received buprenorphine 0.02mg/ kg and group B received 0.9% saline) and vice versa 32 
on day 3. Pain scores and food consumption were measured at 30, 90 and 360 mins after the 33 
administration of buprenorphine. Blood samples were taken at the same time and plasma 34 
buprenorphine concentration was measured by liquid chromatography- mass spectrometry. Data were 35 
statistically analysed as non-parametric and level of significance was set as P<0.05. 36 
Results: There were no major side effects after buprenorphine administration. Buccal pH values ranged 37 
between 8.5-9.1 and stomatitis disease activity index 10-22 (17.8+/- 4.5) with the scale ranging from 0-38 
30. The maximum buprenorphine plasma concentration (14.8 ng/ ml) was observed 30 minutes after 39 
administration and there was low interindividual variability.  There was a significant difference 40 
between baseline pain scores compared to pain scores after buprenorphine (P<0.05) and between the 41 
saline and buprenorphine group at 30 mins (p=0.04) and 90 mins (P=0.04). There was also a significant 42 
effect of stomatitis index on pain score. Regarding the pharmacokinetic parameters, cats with stomatitis 43 
showed lower bioavailability and shorter absorption half-life after buccal administration of 44 
buprenorphine compared to normal cats in previous studies. 45 
Conclusion and clinical relevance: Buccal administration of buprenorphine in cats with 46 
gingivostomatitis produces an analgesic effect and low interindividual variability in plasma 47 
concentration and it can be incorporated in the multimodal analgesia plan of cats with 48 
gingivostomatitis. 49 
Introduction 50 
Pain management is the cornerstone of veterinary practice and constitutes not only a professional 51 
obligation but also a way to enhance animals’ quality of life. In the recent years, there has been increased 52 
interest into pain assessment and management in cats that have been historically undertreated for pain 53 
compared to other species.1-3 54 
Opioids play an important role in the multimodal approach to pain management in cats with 55 
buprenorphine being one of the drugs most widely used.4 Buprenorphine, a highly lipophilic semi 56 
synthetic partial agonist at μ (mu) opioid receptors, is considered a unique drug with complex 57 
pharmacology.5 It is the most commonly used opioid in small animal practice in the UK,1 being also 58 
widely used in the vast majority of continental Europe, Australia and South Africa.2, 6 Common 59 
morphine and hydromorphone side effects such as nausea, vomiting and salivation are rarely seen after 60 
buprenorphine7. This advantage, alongside with its efficacy and long duration of action8, 9 justifying its 61 
popularity. 62 
In feline patients, studies have proven that the buccal route of administration (OTM) of buprenorphine 63 
shows a bioavailability similar to the intravenous (IV) and intramuscular (IM) routes.10-12 According to 64 
Robertson et al (2005),10 the analgesia provided by the buccal administration is comparable to the one 65 
of alternative routes. However, among others the study from Giordano et al. (2010)13 demonstrated 66 
inferior analgesic effect of the buccal route compared to IV and IM after ovariectomy and Santos et al14 67 
found less sedative effect after buccal administration of dexmedetomidine and buprenorphine 68 
compared to IM route. 69 
The systemic absorption of buprenorphine after buccal administration depends on the mucosal pH. 70 
Buprenorphine is a weak base pKa (8.24) and therefore an alkaline environment, such as the cat’s oral 71 
cavity with pH between 8 and 9, favours its unionised form and enhances its bioavailability by avoiding 72 
the first pass elimination.10, 15 73 
The blood-sampling site has also an impact on buprenorphine concentration–time profile. Following 74 
buccal administration in cats, venous blood sampling from a jugular site is not an acceptable substitute 75 
for arterial blood sampling,16 as the perfusion of the oral mucosa drains from the same vein resulting 76 
in overestimation of drug’s systemic availability. The above can explain the high bioavailability of 77 
buprenorphine (116%) found in previous studies10 following buccal administration as external jugular 78 
was used for sampling.   79 
Severe inflammation of the oral cavity, described with the term gingivostomatitis,17 is a multifactorial 80 
disease often seen in feline patients and it can be a chronic, devastating and painful condition. The exact 81 
aetiology of the condition is unknown, with environmental factors, bacterial and viral infection being 82 
most often implicated,18 though neoplastic, autoimmune, developmental and congenital conditions can 83 
be recognised as co-factors as well. Clinical signs include oral pain, halitosis, dysphagia, anorexia and 84 
weight loss, while some cats are euthanized because of poor quality of life.19 Treatment of 85 
gingivostomatitis is mainly symptomatic and involves antibiotics, corticosteroids, opioids, non-86 
steroidal anti- inflammatory agents (NSAIDs), laser thermoablation, cyclosporine, oral surgery and 87 
tonsillectomy. Plasmapheresis, human immunoglobin and feline interferon omega have also been 88 
used.20 It is not known whether the presence of gingivostomatitis affects the saliva pH and thereby the 89 
absorption and the bioavailability of buprenorphine after buccal administration.  90 
 We designed a saline-controlled crossover efficacy and pharmacokinetic study in cats with 91 
gingivostomatitis to assess whether the presence of oral inflammation in the oral cavity affected the 92 
rate of oral transmucosal absorption, the overall systemic uptake and the analgesic efficacy of 93 
buprenorphine. Our alternative hypothesis was that there would be a difference in analgesia between 94 
the buprenorphine and saline groups after buccal administration, with buprenorphine providing 95 
superior analgesia. The prevalence of feline gingivostomatitis in the UK is 0.7%, but appears to be much 96 
higher (13.1%) in studies in United States and Southern Europe.18 Due to the higher prevalence of oral 97 
diseases in Southern Europe we recruited patients at the Aristotle University (Greece). 21 98 
 99 
Materials and methods  100 
The study was designed as a randomised, prospective, saline-controlled, blinded crossover study. The 101 
design is summarised in Figure 1. Ethics approval was granted by the Aristotle University of 102 
Thessaloniki, Greece and written owner consent was obtained for this clinical trial. 103 
Six client owned adult cats, ASA (American Society of Anaesthesiologists) physical status I or II, with 104 
evidence of oral inflammation were included in the study. No abnormal finding other than signs of 105 
gingivostomatitis was detected during physical examination. The cats had not received any opioids 106 
five days prior their arrival. Concurrent NSAIDs and/or antibiotics course were not exclusion criteria. 107 
Allocation of the first treatment was randomised by the means of sealed envelopes containing the 108 
number of each cat. The first three chosen by a blinded investigator were assigned to group A and the 109 
rest to group B. 110 
On day 1, physical examination was performed and baseline pain scores were recorded, according to a 111 
modified BOTUCATU pain scale22 (range from 0 to 27, Appendix 1). All cats were, subsequently, 112 
sedated with 0.02mg/kg medetomidine intramuscularly (IM) (Sedastart, Animalcare). During sedation, 113 
oral pH was measured with pH stripes (Simplex Health), oral lesions were staged and mapped using a 114 
dental examination form and stomatitis disease activity index23 (Appendix 2, 3). An intravenous 115 
peripheral catheter (22G, 25mm. Jelco, Smiths Medical) was placed in a cephalic vein to facilitate blood 116 
sampling and to decrease any additional discomfort for the patients. Sedation was reversed with 0.05 117 
mg/kg of atipamesole (Sedastop, Animalcare) IM. The catheters were flushed every 4 hours with 2ml 118 
of heparinised saline to secure their patency and a light bandage was placed for protection. 119 
On day 2, the cats from group A received 0.02 mg/kg of buprenorphine (group BUP, Buprecare, 120 
Animalcare) by buccal route and group B received equal volume of  0.9% saline (group SAL, Vetivex1, 121 
Dechra Animal Products) by the same route. Both treatments were administered with a 1 ml syringe 122 
(B. Braun medical) in the right cheek pouch by the principal investigator (TS) that was blinded to 123 
treatment allocation. Cats were assessed for the presence of hypersalivation, mydriasis, grooming 124 
activity and food consumption (yes/no) 30, 90 and 360 minutes following the treatment administration. 125 
Pain assessments were performed by the same investigator at the same times using the same scale 126 
(Modified BOTUCATU pain scale) as for baseline and for day 1. 127 
Blood samples were collected by the assessor (MK), who was aware of treatment allocation, 30, 90 and 128 
360 mins after buprenorphine buccal administration, but not after saline administration. Following pain 129 
scoring, samples were taken from the cephalic catheter after 2 ml of blood were aspirated to ensure a 130 
non-diluted blood sample. One ml of blood was collected in potassium EDTA blood tubes (Vetlab). The 131 
samples were centrifuged (Centrifuge Heraeus -Christ GmbH Osterode, Harz Simplex, GE) for eight 132 
minutes at 4039g within 30minutes after collection. The plasma (0.5 to 0.7 mL) was separated and stored 133 
in -80 0 C (Model 725, Thermo-Forma) in labelled Eppendorf tubes. 134 
On day 3, the alternative treatment was administered, with group A receiving the 0.9% saline treatment 135 
and group B receiving 0.02 mg /kg buprenorphine buccally, and the same procedure as on day 2 was 136 
followed. 137 
Plasma samples were shipped to the UK on dry ice and analysed by St Georges University in London. 138 
Plasma buprenorphine was measured using a validated liquid chromatography – tandem mass 139 
spectrometry method (LC/MS/MS),24  initially validated in man. The method was revalidated for feline 140 
plasma and met standards for sensitivity, linearity, precision, accuracy and stability generally accepted 141 
in bioanalytical chemistry.25 The lower limit of quantification of the assay was 0.025 ng/mL. 142 
Population pharmacokinetic modelling was performed with Phoenix NMLE®, version 1.3, Certara 143 
(Princeton, NJ, USA). Briefly, a two-compartmental model was built to be simultaneously fitted to the 144 
plasma buprenorphine concentration-time data from the present study (sparse sampling) and those 145 
from a previously published study performed in healthy cats administered the same dose of 146 
buprenorphine intravenously and by the buccal route (rich sampling).26Full description of the joint 147 
population PK model is provided in Appendix 4. The goal of including external IV and buccal route 148 
data in the PK model was to leverage information (clearances and volumes of distribution assumed to 149 
be distributed similarly in stomatitis and healthy cats) and increase the number of degree of freedom, 150 
as done in Pelligand et al.27This allowed the fitting of the most likely plasma concentration time-curve 151 
in sparsely sampled cats and the estimation of bioavailability and absorption rate constant in the study 152 
with stomatitis cats. 153 
 154 
 155 
Statistical analysis 156 
A commercially available programme was used for the statistical analysis (IBM SPSS Statistics 22). Data 157 
distribution was assessed for normality graphically and by the results of Kolmogorov -Smirnov 158 
statistic. Due to violation of the assumption of normality, the Wilcoxon matched -pairs signed rank test 159 
was used was used to compare pain scores obtained as baseline, after saline and after buprenorphine 160 
administration and at 30, 90 and 360 mins. The level of significance was set as P < 0.05.  Pharmacokinetic 161 
parameters distributions were compared between cats with gingivostomatitis and normal cats from a 162 
previous study26 using the Mann-Whitney U-test. 163 
Correlation analysis was used to describe the strength and the direction of the linear relationship 164 
between variables. Spearman Rank Order Correlation was used for non-parametric data testing of 165 
correlation between stomatitis activity index score and both pH and pain scores. Food consumption 166 
(yes/no) was tested at each time point with a Fisher’s exact test. 167 
  168 
Results 169 
Six, client owned, adult cats were included in this clinical study, four male neutered and two female 170 
neutered. Their age ranged from 7 to 10 years (mean 9.1years) and their body weight ranged from 4 to 171 
7 kg (mean 5.1kg). Two of the cats were receiving antibiotics, one of them was also receiving meloxicam 172 
for their stomatitis, and the last dose was given 48 h before presentation. 173 
No adverse effects were noted in this study except hypersalivation in two of the cats after the 174 
administration of buprenorphine that resolved within minutes. All cats developed mydriasis within 5 175 
minutes after the administration of buprenorphine, except in one cat in which this could not be 176 
evaluated due to bilateral enucleation. Mydriasis persisted for several hours after buprenorphine 177 
administration. Mydriasis does not correlate with analgesia or antinociception.9 178 
The oral pH values ranged from 8.5 to 9 and the stomatitis disease activity index ranged from 10 to 22 179 
(mean 17.8+/- 4.5). Three of the cats had partial mouth extractions of the premolar and molar teeth and 180 
three had previously full mouth extractions. However, that was completed at least a year before 181 
presentation. The positive correlation between the variables of pH and stomatitis disease index and pH 182 
was not significant (P= 0.152). 183 
Food consumption evaluation was part of the total pain scores. Small amount of wet and dry food was 184 
offered repeatedly at these timepoints   Overall at 30 mins, all cats in the buprenorphine groups ate 185 
some wet food compared to 2 in the saline groups (P= 0.061). At 90 minutes, cats treated with 186 
buprenorphine had a significantly higher chance to eat than the ones with saline (6 cats for 187 
buprenorphine vs 1 saline, P = 0.0152).  There was no difference at 360 minutes (2 cats for buprenorphine 188 
vs 3 cats for saline, P = 0.54). None of the cats started eating dry food at any time point. 189 
Pain scores (figure 2) decreased significantly with buprenorphine (BUP) and saline (SAL) 190 
administration compared to baseline (BSL, P = 0<.001).  When testing each time point, the pain scores 191 
for the BUP group were significantly lower than BSL at 30 mins (P = 0.0007) and 90 mins (P=0.011) and 192 
were significantly lower than SAL at 30 mins (P=0.04) and at 90mins (P=0.04), but not at 360 mins 193 
(P=0.09).  Linear mixed model also revealed a significant effect of stomatitis index score on pain score 194 
(P=0.001). 195 
The time of maximum buprenorphine plasma concentrations in cats with gingivostomatitis was at the 196 
30-mins blood sample when concentrations ranged from 274 to 1 621 ng/ mL. One cat (10-year female 197 
neutered 4.2kg cat treated with clindamycin, meloxicam, dental score 18) had a very high plasma 198 
concertation (84 979 ng/mL). This data point was excluded from the analysis on the basis that such high 199 
plasma concentrations were not reached even in early 1 and 3-minute samples after IV administration22 200 
and is likely to result from contamination of the sample. The most likely buprenorphine plasma 201 
concentration-time plot for the cats with gingivostomatitis is shown in figure 3.  For all parameters 202 
listed below, the inter-individual variability (IIV %) is reported immediately following each estimate 203 
where appropriate. Pharmacokinetic parameter (Table 1) estimates for clearance, intercompartmental 204 
clearance, volume of distribution of the central and peripheral compartment displayed low inter-205 
individual variability even in a mixed group and were close to values previously reported.26 206 
The pharmacokinetic parameters are presented in Table 1 and described in Appendix 4 (figure 4).  207 
 208 
Discussion 209 
During this study, no side effects were identified, except hypersalivation in two cats. All cats, except 210 
the one that had bilateral enucleation, developed mydriasis.  211 
There is a lack of evidence in veterinary literature on whether oral inflammation affects buccal pH 212 
values. The values of buccal pH in our study ranged between 8.5 and 9.1 and are relatively lower 213 
compared to Robertson’s study10 (p H =9.0) but higher compared to Hedges’s26 (pH =8.0). A correlation 214 
between the buccal pH and the stomatitis disease activity index was not identified. An increase in pH 215 
is associated with increased salivation in humans28 due to an increase of sodium and bicarbonate.29  In 216 
cats, stomatitis is often related with sings of hypersalivation.17  217 
Cats showed increased appetite at 30 and 90 mins after buprenorphine administration, which could be 218 
due to additional analgesia or euphoria. An increase in food consumption is a rare manifestation of 219 
pain in cats.30 None of the cats ate dry food which could be due to insufficient pain relief or to preference 220 
as cats were offered simultaneously wet and dry food. The influence of a hospital environment should 221 
also be considered. Some cats remain unresponsive and passive in new environments or can be 222 
hyperactive.31, 32 Increased food intake would be an important benefit, considering that compromised 223 
nutrition is one of the most important problems encountered with gingivostomatitis.33 224 
Pain scores following buprenorphine administration were lower than at baseline and following saline 225 
administration. This can be attributed to pain relief as well as the euphoria produced by opioids. In 226 
addition, local effect of buprenorphine needs to be considered since a study in humans found that 227 
buprenorphine decreased the postoperative pain and increased the duration of analgesia when added 228 
to the inferior alveolar nerve block for dental surgery, compared to intramuscular administration.34 The 229 
fact that the pain scores were lower after saline administration compared to baseline, could be 230 
attributed to acclimatisation in the new environment, as well familiarisation with the pain scoring 231 
process and the evaluator. The effect of stomatitis index on pain score was expected, as cats with more 232 
severe stomatitis are expected to be more painful. Our alternative hypothesis that pain scores would be 233 
lower following buprenorphine than following saline was confirmed, as there was a significant 234 
difference at 30 and 90 mins. The plasma buprenorphine concentration at 360 mins may have been 235 
inadequate to provide analgesia. In any case, the results may suggest that the duration of effect of 236 
buprenorphine at the dose used may be shorter than previously reported. 237 
The time of maximum plasma buprenorphine concentration was 30 minutes following administration 238 
and pharmacokinetic analysis showed low interindividual variability with values close to those 239 
obtained by Hedges et al26  in cats with normal oral mucosa. Transmucosal drug absorption, though, 240 
depends on many different factors like its concentration and the mucosal contact time.35 Buprenorphine 241 
was administered in the cheek pouch but the degree of inflammation on the specific area could not be 242 
determined. Inflammation-induced vasodilation could have led to an earlier maximum concentration 243 
that we were unable to detect as our first blood sample was at 30 min. In addition, cats might have 244 
swallowed or spitted a portion of the drug, as they were sensitive in handling of the head and did not 245 
tolerate their mouth to be held closed after treatment. The formulation used in this study was a multi-246 
dose vial (Buprecare, Animalcare,) containing 0.135% chlorocresol as a preservative and it is possible 247 
that the preservative free buprenorphine could be better tolerated, while there is no difference 248 
regarding their  pH among the formulations.36   The multi-dose vials are commonly used in practice due 249 
to cost effectiveness and easy usage and storage.  250 
 In our study, the mean absorption half-life of buprenorphine was longer compared to Hedges et al. ,26 251 
which included normal cats. However, there was no significant difference in bioavailability, although 252 
the present study may have been underpowered to detect a difference. The difference in absorption 253 
rate could be due either to the different formulations of buprenorphine that were used in the two 254 
studies, to the actual modalities of administration or an effect of the higher pH and the presence of 255 
gingivostomatitis.  256 
The study had several limitations. The lack of a sensitive and validated pain scale for oral pain is a 257 
major limitation. UNESP-Botucatu scale is the only pain scoring system for cats with published data on 258 
reliability, validity and sensitivity30 and we modified it for oral pain using the oral cavity as the painful 259 
reference point and the head and neck area as the surrounding tissues. We omitted the blood pressure 260 
measurement because it could be stressful and unreliable when repeated in frequent intervals. The 261 
maximum point of our pain scale was 27 instead of 30 in the original scale. The small sample size is 262 
another limitation that could have affected our statistical analysis. Furthermore, the use of historical 263 
data for modelling in lieu constitutes one more limitation, as is the use of data from another study that 264 
were obtained under different conditions and analysed using a different assay, despite that they were 265 
remodelled using the study population model. The fact that one of the cats was receiving meloxicam 266 
constitutes another limitation. However, the last dose was given 48h before presentation and the 267 
baseline pain score of this cat that could have been potentially affected was similar to the rest of the 268 
cats. In addition, there is no possibility that co-administration of NSAIDs interferes with the 269 
quantitative analysis of buprenorphine by liquid chromatography mass spectrometry because of the 270 
high specificity of the method. Finally, the values of buccal pH were also obtained on day 1 after the 271 
administration of medetomidine that could have also affected the value, so we are not aware of the 272 
actual pH value on the time of buprenorphine administration.  273 
 274 
 275 
Conclusion  276 
Buccal administration of buprenorphine in cats with gingivostomatitis produces an analgesic effect and 277 
has low interindividual variability regarding plasma concentration. Further studies are needed to 278 
elucidate the role of oral inflammation on buccal drug absorption in cats as well as the potential benefit 279 
and appropriateness of opioids compared to the current analgesia alternatives such as NSAIDs. 280 
Furthermore, considering that sublingual buprenorphine constitutes an effective treatment of chronic 281 
pain in humans 37 and that subcutaneous buprenorphine prevented hyperalgesia in cats,38 studies on 282 
the long-term use of buprenorphine by the buccal route in cats with chronic gingivostomatitis and the 283 
evaluation of the potential benefits and side effects would be of clinical interest. 284 
 285 
 286 
 287 
 288 
Supplementary material 289 
Appendix 1: UNESP-Botucatu Multidimensional Composite Pain Scale for assessing postoperative 290 
pain in cats, modified to assess oral pain. 291 
 292 
Subscale 1: PAIN EXPRESSION (0 – 12)  
Miscellaneous 
behaviour 
Observe and mark the presence of the behaviours listed below  
A - The cat is laying down and quiet, but moving its tail  
B - The cat contracts and extends its thoracic limbs and/or contracts its neck muscles             
C - The cat’s eyes are partially closed (eyes half closed)  
D - The cat licks and/or bites the surgical wound  
  
•                                                    All above behaviours are absent  
•                                                  Presence of one of the above behaviours  
  
A  
B  
C  
D  
  
0  
1  
                                                       Presence of two of the above behaviours  2  
                                                       Presence of three or all of the above behaviours  3  
      
Reaction to 
palpation of 
the area 
around the 
mouth cavity 
• The cat does not react when the mouth is touched or pressed;  
 
• The cat does not react when the area around the mouth is touched, but does react when it 
is pressed. It may vocalize and/or try to bite   
 
• The cat reacts when the mouth is touched and when pressed. It may vocalize and/or try to 
bite  
• The cat reacts when the observer approaches the mouth. It may vocalize and/or try to bite     
The cat does not allow palpation around mouth cavity 
0 
1  
 
  2  
3  
      
Reaction to 
palpation of 
the head   
• The cat does not react when the head is touched 
• The cat does not react when the head and neck are touched, but does react when it is 
pressed. The neck is tense  
• The cat reacts when the head and neck are touched and when pressed. The neck is tense  
• The cat reacts when the observer approaches the head It may vocalize and/or try to bite      
The cat does not allow palpation of the head and neck 
0  
1  
2  
3  
      
vocalisation • The cat is quiet, purring when stimulated, or miaows interacting with the observer, 
but does not growl, groan, or hiss  
• The cat purrs spontaneously (without being stimulated or handled by the observer)  
• The cat growls, howls, or hisses when handled by the observer (when its body 
position is changed by the observer)  
• The cat growls, howls, hisses spontaneously (without being stimulated or handled by 
the observer)  
0  
1  
2  
3  
 
 293 
                                                       Subscale 2: PSYCHOMOTOR CHANGE (0 – 12)  
posture • The cat is in a natural posture with relaxed muscles (it moves normally)  
• The cat is in a natural posture but is tense (it moves little or is reluctant to move)  
• The cat is sitting or in sternal recumbency with its back arched and head down; or   
    The cat is in dorso-lateral recumbency with its pelvic limbs extended or contracted  
0  
1  
2  
   The cat frequently alters its body position in an attempt to find a comfortable posture  3  
      
comfort 
• The cat is comfortable, awake or asleep, and interacts when stimulated (it interacts with the observer 
and/or is interested in its surroundings)  
• The cat is quiet and slightly receptive when stimulated (it interacts little with the observer and/or is 
not very interested in its surroundings)  
• The cat is quiet and “dissociated from the environment” (even when stimulated it does not interact 
with the observer and/or has no interest in its surroundings)  
     The cat may be facing the back of the cage  
0  
1  
2  
   The cat is uncomfortable, restless (frequently changes its body position), and slightly receptive 
when stimulated or “dissociated from the environment”   The cat may be facing the back of the 
cage  
3  
      
activity • The cat moves normally (it immediately moves when the cage is opened; outside the cage it moves 
spontaneously when stimulated or handled)  
• The cat moves more than normal (inside the cage it moves continuously from side to side)                            
• The cat is quieter than normal (it may hesitate to leave the cage and if removed from the cage tends to 
return, outside the cage it moves a little after stimulation or handling)  
0  
1
2  
   The cat is reluctant to move (it may hesitate to leave the cage and if removed from the cage tends to 
return, outside the cage it does not move even when stimulated or handled)  
3  
      
attitude 
Observe and mark the presence of the mental states listed below   
A - Satisfied: The cat is alert and interested in its surroundings (explores its surroundings), friendly 
and interactive with the observer (plays and/or responds to stimuli)        
       *The cat may initially interact with the observer through games to distract it from the pain. Carefully 
observe to distinguish between distraction and satisfaction games              
B - Uninterested: The cat does not interact with the observer (not interested by toys or plays a little; 
does not respond to calls or strokes from the observer)  
* In cats, which don’t like to play, evaluate interaction with the observer by its response to calls and strokes    
C - Indifferent: The cat is not interested in its surroundings (it is not curious; it does not explore its 
surroundings)   
* The cat can initially be afraid to explore its surroundings. The observer needs to handle the cat and 
encourage it to move itself (take it out of the cage and/or change its body position)                        
D - Anxious: The cat is frightened (it tries to hide or escape) or nervous (demonstrating impatience and 
growling, howling, or hissing when stroked and/or handled)                                 
  
A  
B  
C  
D  
 E - Aggressive: The cat is aggressive (tries to bite or scratch when stroked or handled)                                     
  
E
  
                                                             Presence of the mental state A  0  
                                                             Presence of one of the mental states B, C, D, or E  1  
                                                             Presence of two of the mental states B, C, D, or E  2  
                                                             Presence of three or all of the mental states B, C, D, or E  3  
  
Subscale 3: PHYSIOLOGICAL VARIABLES (0 – 3)  
      
Appetite • The cat is eating normally  
• The cat is eating more than normal  
• The cat is eating less than normal  
• The cat is not interested in food  
0  
1  
2  
3  
      
TOTAL SCORE (0 – 27)  
      
 294 
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 296 
 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
 305 
 306 
 307 
Appendix 2: feline dental chart (Holmstrom S, Frost P and Eisner E. Veterinary dental techniques: for 308 
the small animal practitioner. 2nd ed. W. B. Saunders Company, 1998, pp17-18) 309 
 310 
 311 
 312 
 313 
 314 
Appendix 3: Stomatitis disease activity index score. 23 315 
 316 
 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
Appendix 4: Population pharmacokinetic-pharmacodynamic modelling 330 
A classic two-compartment model with first order absorption was the starting point for compartmental 331 
modelling of the buccal route. We used the raw data from a previous publication (Hedges et al. 2013 with 6 332 
healthy cats receiving buprenorphine IV and buccally) to support the PK modelling in clinical cats from which 333 
only 3 blood samples were taken. 334 
 335 
Parameters: CL: body clearance, CL2: inter-compartmental clearance, V1: central volume of 336 
distribution, V2: peripheral volume of distribution, kaBUC_STOM: absorption rate constant in cats with 337 
stomatitis, kaBUC_NORM: absorption rate constant in normal cats, FBUC_STOM: bioavailability in cats with 338 
stomatitis, FBUC_NORM: bioavailability in normal cats. 339 
Goodness of fit: 340 
For each Phoenix NMLE run, plots of goodness of fit were prepared  39. The nested candidate models 341 
were compared on the basis of their biological plausibility, prediction based diagnostics (PRED, 342 
IPRED,), residual-type diagnostics (RES and IRES) and numerical diagnostics (minimisation of the 343 
Objective Function Value (OVF) statistically tested with the Likelihood Test Ratio (was LRT 344 
performed, deltaOVF >6.64; P<0.01, df = 1, or alternatively use the Akaike Information Criterion, AIC) 345 
as well as measures of model stability and adequacy (convergence, precision of the parameters 346 
estimates). 347 
 348 
Statistical description of the model: 349 
Inter-animal variability was characterised assuming that individual parameters were log-normally 350 
distributed around the population typical value (Eq. 1): 351 
𝑃𝑖𝑗 =  𝜃𝑗  × exp (𝜂𝑖𝑗)               (1) 352 
Where Pij is the j-th parameter value for individual i, θj is the typical value for the j-th parameter for 353 
the population and ηij is normally distributed around 0 with a variance of ω2j. To minimise the 354 
residual variability (difference between predicted and observed values), additive and proportional 355 
error models were compared.  356 
Parameters bounded between 0 and 1 (typically bioavailabilities, noted F) were expressed and 357 
estimated in the model after a logit transform and the typical value of F (θ_F) was back-converted as 358 
in equation 2 to yield final estimate.  359 
𝐹𝑖 = 𝑖𝑛𝑣 𝑙𝑜𝑔𝑖𝑡 (𝜃𝐹 + 𝜂𝐹𝑖)     (2) 360 
Where Fi is the inverse logit of θF, the typical value of the bioavailability, and ηFi is the residual for 361 
the ith invidual. 362 
The coefficient of variation of the PK parameter was approximated as follows (Eq. 3): 363 
𝐶𝑉(%) =  √𝑒𝑥𝑝 (𝜔2) − 1  × 100%       (3) 364 
Visual predictive checks were built to evaluate the performance of the final model by comparing the 365 
median of the simulated (n=5000) plasma concentrations with the observed data (+/- 5th and 95th 366 
percentiles). 367 
PK modelling  368 
Base model development for the buccal administration 369 
First, a 2 compartment model was written to fit simultaneously the IV and the buccal route to allow 370 
estimation of the physiological PK parameters common to the three routes of administration (namely 371 
CL, the total body clearance; V, the volume of the central compartment; CL2, the intercompartmental 372 
clearance and V2, the volume of the peripheral compartment), as well as the buccal absorption rate 373 
constants (kaBUC) and the absolute buccal bioavailabilities (FBUC). The typical value θj and individual ηij 374 
were fixed to reduce the number of parameters to estimate in the modelling of the complex SC 375 
absorption.  376 
Table1: Comparison of rival models for joint IV and buccal buprenorphine model and selection of 377 
best model 378 
Joint model OFV (-
2LL) 
AIC Comment 
Combined IV and buccal, 
proportional error 
221 255 Best model 
Combined IV and buccal, 
additional error 
443 477 
 
 379 
PK parameters estimates (see also Table 1 in manuscript): 380 
The two routes of administration shared four central PK parameters; clearance (CL = 1.26 L/ kg / hour, 381 
1.1%), volume of distribution of the central compartment (V1 = 0.65 L/kg, 0.9%), intercompartmental 382 
clearance (CL2 = 1.19 L /kg/hour, 2.3%) and peripheral volume of distribution (V2 = 6.96 L/ kg, 7.8%) 383 
with a common proportional residual error term.  384 
For PK parameters specific to the buccal treatment, the mean bioavailability in the cats with 385 
gingivostomatitis with the current formulation (Buprecare®, animalcare) was 19.5% (IIV 65.7%) 386 
compared to 28.8% (IIV 19.6%) in the normal cats in the study by Hedges et al26, in which another 387 
formulation was used (Buprenex® Injectable; Reckitt Beckiser Pharmaceuticals). This difference was not 388 
significant (P = 0.31). The absorption rate constant in cats with gingivostomatitis was 0.57/hour, yielding 389 
an absorption half-life of 1.2 hours. For the normal cats in the study by Hedges et al. 26, the absorption 390 
rate constant was 1.39/hour, yielding a significantly shorter  absorption half-life of 0.49 hours. 391 
Results and goodness of fit plots: 392 
The goodness of fit figures for the final PK model fitting (buprenorphine and metabolite) are included 393 
thereafter:  394 
- Fig suppl. 1: observed values vs population prediction,  395 
- Fig suppl. 2: observed values vs individual predictions,  396 
- Fig suppl. 3: conditional weighted residuals vs time after dose,  397 
- Fig suppl. 4: conditional weighted residuals vs population prediction,  398 
- Fig suppl. 5: individual observed concentrations and model predictions vs time, 399 
 400 
Fig suppl. 1 (observed values vs population predictions PRED) 401 
Legends: CObs_A_IV: buprenorphine after IV administration (Hedges et al, 2013), CObs_B_OTM: 402 
buprenorphine after buccal administration (Hedges et al, 2013), CObs_C_OTM: buprenorphine after 403 
buccal administration (present study), DV = dependent variable (observed value), PRED = population 404 
predictions, IPRED = individual predictions 405 
 406 
 407 
 408 
 409 
 410 
Fig suppl. 2 (observed values vs individual predictions IPRED) 411 
 412 
413 
 414 
Fig suppl. 3 (conditional weighted residuals vs time after dose)  415 
 416 
 417 
Fig suppl. 4 (conditional weighted residuals vs population prediction) 418 
 419 
 420 
 421 
 422 
 423 
 424 
 425 
Fig suppl. 5: Invididual observed concentrations and model predictions vs time. Cats 2 to 7 has 426 
gingivostomatitis and were sparsely sampled after administration of buprenorphine 0.02 mg/kg 427 
buccally (Formulation: Buprecare, Animalcare). Cats 11 to 16 were normal cats and were densely 428 
sampled after administration of 0.02 mg/kg buprenorphine IV (CObs_A) and buccally (Cobs_B) 429 
(Formulation: Buprenex, Reckitt Beckiser Pharmaceuticals) 430 
 431 
 432 
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 434 
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